Monday, March 17, 2025 | 01:50 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection

Image

Capital Market
Glenmark Pharmaceuticals has been granted tentative approval by the United States Food & Drug Administration for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL), a generic version of FASLODEX1 Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP.

According to IQVIATM sales data for the 12 month period ending December 2018, the FASLODEX Injection, 250 mg/5 mL (50 mg/mL) market2 achieved annual sales of approximately $533.3 million.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 07 2019 | 9:16 AM IST

Explore News